Cancer-linked IDH1/2 variants have reduced wild-type (wt) activity, but gain the ability to convert 2OG to the ‘oncometabolite’ 2-hydroxyglutarate (2HG) (Fig. 1a), resulting in substantially elevated 2HG levels in tumours bearing IDH mutations6. This evidence concerns the gene IDH2 and cancer.